Words of Wisdom. Re: Randomized Controlled Trial of Early Zoledronic Acid in Men with Castration-sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance).
作者信息
Kimura Takahiro, Egawa Shin
机构信息
Department of Urology, Jikei University School of Medicine, Tokyo, Japan.
Department of Urology, Jikei University School of Medicine, Tokyo, Japan.
出版信息
Eur Urol. 2016 Apr;69(4):754-5. doi: 10.1016/j.eururo.2016.01.019. Epub 2016 Feb 18.
PMID:26972498
Abstract
摘要
相似文献
1
Words of Wisdom. Re: Randomized Controlled Trial of Early Zoledronic Acid in Men with Castration-sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance).
Eur Urol. 2016 Apr;69(4):754-5. doi: 10.1016/j.eururo.2016.01.019. Epub 2016 Feb 18.
2
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).
J Clin Oncol. 2014 Apr 10;32(11):1143-50. doi: 10.1200/JCO.2013.51.6500. Epub 2014 Mar 3.
3
Is time to first skeletal-related event the best primary end point in the assessment of bisphosphonate efficacy in patients with castration-sensitive prostate cancer?
J Clin Oncol. 2014 Nov 10;32(32):3684-5. doi: 10.1200/JCO.2014.56.2017. Epub 2014 Sep 15.
4
Reply to F. Valcamonico et al.
J Clin Oncol. 2014 Nov 10;32(32):3685. doi: 10.1200/JCO.2014.57.3808. Epub 2014 Sep 15.
5
Complete clinical and biological response to zoledronic acid in castrate-resistant prostate cancer metastatic to bone.
Anticancer Drugs. 2012 Jan;23(1):141-2. doi: 10.1097/CAD.0b013e32834bede5.
6
Zometa in the treatment of diseminated prostate cancer.
Acta Chir Iugosl. 2005;52(4):119-21. doi: 10.2298/aci0504119d.
7
Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
Urol Oncol. 2006 Jan-Feb;24(1):4-12. doi: 10.1016/j.urolonc.2005.06.020.
8
Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
Expert Rev Anticancer Ther. 2009 Sep;9(9):1211-8. doi: 10.1586/era.09.95.
9
[Use of zoledronic acid in patients with prostate cancer bone metastases: control of pain and musculoskeletal complications].
Urologia. 2011 Oct-Dec;78(4):300-4. doi: 10.5301/RU.2011.8877.
10
Explaining objective responses to zoledronic acid.
Anticancer Drugs. 2012 Nov;23(10):1121. doi: 10.1097/CAD.0b013e3283587c13.
Zotero 插件